---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-101975"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:57:28.078370+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Journey Medical regains Nasdaq equity compliance after $19M Maruho license

## Summary
- Previously disclosed Nasdaq Staff notified Company of non-compliance with $2.5M stockholders' equity requirement on August 15, 2023.
- On August 31, 2023, entered exclusive license agreement with Maruho for Qbrexza; Maruho paid $19M.
- Company now believes it satisfies Stockholders' Equity Requirement and awaits formal Nasdaq determination.
- Company had deadline of September 29, 2023 to submit compliance plan if needed.

## SEC filing metadata
- accession: 0001104659-23-101975
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465923101975/0001104659-23-101975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465923101975/tm2326458d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-101975
- JSON: https://secwatch.observer/filing/0001104659-23-101975.json
- Plain text: https://secwatch.observer/filing/0001104659-23-101975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.